Posters
(results will display both Free Papers & Poster)
Case report: unilateral Mooren ulcer revealing hepatitis C
Poster Details
First Author: H.Alaoui Ismaili MOROCCO
Co Author(s): Z. Hammoumi I. Essemlali R. Nasrouni L. Maaloum B. Allali A. Kettani
Abstract Details
Purpose:
Clinical manifestations , diagnosis and therapeutic modalities of Mooren ulcer in a patient who consults for a painful red eye at the emergency Department of the 20th August 1953 Hospital in Casablanca (Morocco)
Setting:
Pediatric ophthalmology department; August 20th,1953 hospital Ibn Rochd University ,Hospital Center Faculty of Medicine and Pharmacy , Hassan II University Casablanca (Morocco).
Methods:
We present the case of a 74 years old patient, consulting for a painful red eye associated with a decrease of the visual acuity and tearing evolving since 3 weeks
We conducted a general, and an ophthalmological examination that founds(left eye):
VA: 2/10
Conjunctival hyperemia, BUT<10 sec, Shirmer test: positive.
marginal corneal ulcer making 5mm / 2mm, circumferential and digging, associated with diffuse SPK.
nuclear cataract and posterior subcapsular
Normal fundus.
The ulcer was treated with antibiotics, artificial tears and without improvement
Results:
An infectious and immunological assessment was carried out:
Hepatitis C serology: positive
Once the diagnosis of hepatitis C confirmed
topical corticosteroid therapy was initiated
Hepatitis C treatment: ribavirin and interferon
The evolution was marked by the improvement of the visual acuity (4/10) and healing of the ulcer with early onset of neovascularization.
Conclusions:
Mooren's ulcer is a chronic, unilateral or bilateral peripheral corneal ulceration.
The exact pathophysiology is poorly known but the autoimmune hypothesis is the subject of a consensus, it would involve humoral and cellular immunity.
Infrequent pathology that may compromise the visual prognosis.
Hepatitis C is responsible for Mooren's ulcer by a mechanism of cross-immunity.
Treatment: early with etiological treatment.
Financial Disclosure:
None